Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
數字之外:4位分析師討論Entrada Therapeutics股票
In the preceding three months, 4 analysts have released ratings for Entrada Therapeutics (NASDAQ:TRDA), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中,4位分析師發佈了對Entrada Therapeutics(納斯達克:TRDA)的評級,呈現了從看好到看淡的各種觀點。
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
下表提供了分析師最近的評級概述,爲了全面了解過去30天的情緒變化並與前幾個月進行比較,提供了深入的見解。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.75, a high estimate of $28.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 5.81% from the previous average price target of $21.50.
分析師評估的12個月價目標揭示了進一步的見解,平均目標爲22.75美元,最高估值爲28.00美元,最低估值爲18.00美元。目前的平均價目標已經較之前的21.50美元的目標上漲了5.81%,顯示出積極的變化。
Exploring Analyst...
分析...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。